Starting from an unbiased loss-of-function screening that identified SGK2 as a druggable modulator of PT sensitivity in EOC cells, we characterized the role of this under-studied kinase in the control of autophagy, an escaping strategy activated by cancer cells to survive under PT treatment. The gene discussed is SGK2; the disease is cancer.